DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Priliximab
Priliximab
Anticuerpos Monoclonales: Desarrollo Físico Y Perspectivas Terapéuticas
Nuevos Medicamentos De Origen Biotecnológico
The Two Tontti Tudiul Lui Hi Ha Unit
WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
Ep 3178848 A1
A Human CD4 Monoclonal Antibody for the Treatment of T-Cell
(INN) for Biological and Biotechnological Substances
Infliximab for Crohn's Disease
INN Working Document 05.179 Update 2011
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
International Nonproprietary Names (Inn) for Biological and Biotechnological Substances
(INN) for Biological and Biotechnological Substances
A Free F1-Remicade F1-Renicade
WO 2014/144600 A2 18 September 2014 (18.09.2014) P O P CT
WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
(12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep
Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
Top View
Supporting Information
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Wo 2010/095940 A2
Pharmaabkommen A1 E
(12) Patent Application Publication (10) Pub. No.: US 2015/0322155A1 Zhao (43) Pub
Customs Tariff - Schedule Xxi - 1
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances 2009
Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
(INN) for Biological and Biotechnological Substances
Harmonized Tariff Schedule of the United States (2006) (Rev
A Monoclonal Antibody to Target Regulatory T Cells
Assessment of the Evolution of Cancer Treatment Therapies
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Pharmaceutical Appendix to the Tariff Schedule 2